Samsung BiologicsLtd Future Growth

Future criteria checks 2/6

Samsung BiologicsLtd is forecast to grow earnings and revenue by 15.8% and 12.3% per annum respectively. EPS is expected to grow by 15.7% per annum. Return on equity is forecast to be 11.1% in 3 years.

Key information

15.8%

Earnings growth rate

15.7%

EPS growth rate

Life Sciences earnings growth	25.7%
Revenue growth rate	12.3%
Future return on equity	11.1%
Analyst coverage	Good
Last updated	29 Apr 2024

Recent future growth updates

Recent updates

What Samsung Biologics Co.,Ltd.'s (KRX:207940) P/E Is Not Telling You

Apr 14

With EPS Growth And More, Samsung BiologicsLtd (KRX:207940) Is Interesting

Mar 01

These 4 Measures Indicate That Samsung BiologicsLtd (KRX:207940) Is Using Debt Reasonably Well

Jan 18

What Kind Of Shareholders Own Samsung Biologics Co.,Ltd. (KRX:207940)?

Dec 28

How Much Is Samsung Biologics Co.,Ltd. (KRX:207940) CEO Getting Paid?

Dec 08

Did You Miss Samsung BiologicsLtd's (KRX:207940) Impressive 112% Share Price Gain?

Nov 18

Earnings and Revenue Growth Forecasts

KOSE:A207940 - Analysts future estimates and past financials data (KRW Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	5,598,243	1,373,047	1,029,270	1,677,518	19
12/31/2025	4,920,971	1,175,895	961,780	1,733,753	22
12/31/2024	4,263,529	974,500	975,340	1,593,400	21
12/31/2023	3,694,589	857,691	560,904	1,666,229	N/A
9/30/2023	3,586,607	936,917	90,946	1,142,523	N/A
6/30/2023	3,425,675	825,714	123,290	1,297,787	N/A
3/31/2023	3,210,913	792,869	-127,837	1,056,823	N/A
12/31/2022	3,001,295	798,056	-56,178	953,048	N/A
9/30/2022	2,480,082	507,465	-118,959	758,364	N/A
6/30/2022	2,057,774	510,074	-119,293	574,512	N/A
3/31/2022	1,818,513	479,557	98,246	740,044	N/A
12/31/2021	1,568,007	393,589	33,444	454,596	N/A
9/30/2021	1,499,000	410,493	-186,817	197,495	N/A
6/30/2021	1,322,849	334,801	-248,944	68,957	N/A
3/31/2021	1,218,377	265,297	-204,326	8,415	N/A
12/31/2020	1,164,777	240,975	53,524	202,090	N/A
9/30/2020	1,102,797	355,375	328,082	448,779	N/A
6/30/2020	1,013,033	343,437	164,501	282,599	N/A
3/31/2020	783,424	278,007	-39,485	101,382	N/A
12/31/2019	701,592	202,904	-192,146	10,154	N/A
9/30/2019	566,539	309,564	-260,289	-61,528	N/A
6/30/2019	482,788	238,438	-291,159	-74,876	N/A
3/31/2019	530,136	232,319	-236,087	6,550	N/A
12/31/2018	535,806	224,109	-317,476	-33,017	N/A
9/30/2018	523,843	-103,273	-312,532	56,383	N/A
6/30/2018	550,229	-107,990	-345,042	108,544	N/A
3/31/2018	488,016	-110,558	-411,579	125,412	N/A
12/31/2017	464,629	-96,972	-354,985	149,816	N/A
9/30/2017	403,868	-143,853	N/A	31,356	N/A
6/30/2017	329,199	-156,259	N/A	4,854	N/A
3/31/2017	313,519	-184,194	N/A	-55,446	N/A
12/31/2016	294,622	-176,823	N/A	-62,661	N/A
9/30/2016	218,108	879,382	N/A	-175,568	N/A
6/30/2016	194,360	1,922,710	N/A	-265,573	N/A
3/31/2016	163,426	1,933,611	N/A	-234,771	N/A
12/31/2015	91,278	1,920,179	N/A	-265,514	N/A
12/31/2014	105,149	-95,909	N/A	-108,299	N/A
12/31/2013	43,747	-129,031	N/A	-103,538	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: A207940's forecast earnings growth (15.8% per year) is above the savings rate (2.5%).

Earnings vs Market: A207940's earnings (15.8% per year) are forecast to grow slower than the KR market (28.4% per year).

High Growth Earnings: A207940's earnings are forecast to grow, but not significantly.

Revenue vs Market: A207940's revenue (12.3% per year) is forecast to grow faster than the KR market (9.1% per year).

High Growth Revenue: A207940's revenue (12.3% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: A207940's Return on Equity is forecast to be low in 3 years time (11.1%).

Samsung BiologicsLtd Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Consensus revenue estimates increase by 12%

Consensus revenue estimates increase by 16%

Consensus EPS estimates increase by 13%

Price target raised to ₩843,438

Recent updates

What Samsung Biologics Co.,Ltd.'s (KRX:207940) P/E Is Not Telling You

Samsung Biologics Co.,Ltd. to Report Q1, 2024 Results on Apr 24, 2024

Full year 2023 earnings released: EPS: ₩12,051 (vs ₩11,442 in FY 2022)

Samsung Biologics Co.,Ltd., Annual General Meeting, Mar 15, 2024

Samsung Biologics Co.,Ltd., Annual General Meeting, Mar 15, 2024

Samsung Biologics Co.,Ltd. to Report Fiscal Year 2023 Final Results on Jan 24, 2024

Samsung Biologics Co.,Ltd. to Report Q3, 2023 Results on Oct 25, 2023

Samsung Biologics Announces Executive Appointments

Samsung Biologics Co.,Ltd. to Report Q2, 2023 Results on Jul 26, 2023

First quarter 2023 earnings released: EPS: ₩1,992 (vs ₩2,221 in 1Q 2022)

Consensus revenue estimates increase by 12%

Third quarter 2022 earnings released: EPS: ₩1,815 (vs ₩1,992 in 3Q 2021)

Consensus revenue estimates increase by 16%

Second quarter 2022 earnings released: EPS: ₩2,160 (vs ₩1,837 in 2Q 2021)

GreenLight Biosciences and Samsung Biologics Completes First Commercial-Scale Engineering Run for mRNA Covid-19 Vaccine

High number of new directors

Consensus EPS estimates increase by 13%

High number of new directors

First quarter 2022 earnings: Revenues exceed analyst expectations

Samsung Biologics Co.,Ltd. (KOSE:A207940) completed the acquisition of the remaining 49.9% stake in Samsungbioepis Co,.Ltd from Biogen Inc. (NasdaqGS:BIIB).

Samsung Biologics Co.,Ltd., Annual General Meeting, Mar 29, 2022

Samsung Biologics Co.,Ltd. (KOSE:A207940) reached an agreement to acquire 49.9% stake in Samsungbioepis Co,.Ltd from Biogen Inc. (NasdaqGS:BIIB) for $2.3 billion.

Third quarter 2021 earnings released: EPS ₩1,992 (vs ₩848 in 3Q 2020)

Samsung Biologics showcases its newest CDO process platform, S-Cellerate™, at BPI 2021, offering expedited timeline to IND and BLA

Samsung Biologics Joins Frontier 1.5D Project as Part of 2050 Carbon Neutral Initiative

Second quarter 2021 earnings released: EPS ₩1,837 (vs ₩786 in 2Q 2020)

First quarter 2021 earnings released: EPS ₩922 (vs ₩554 in 1Q 2020)

Full year 2020 earnings released: EPS ₩3,642 (vs ₩3,067 in FY 2019)

With EPS Growth And More, Samsung BiologicsLtd (KRX:207940) Is Interesting

Samsung Biologics Co.,Ltd., Annual General Meeting, Mar 19, 2021

New 90-day low: ₩783,000

Samsung Biologics, National OncoVenture, and Eutilex Obtain IND Approval from FDA

Samsung Biologics Co.,Ltd. to Report Fiscal Year 2020 Results on Jan 26, 2021

These 4 Measures Indicate That Samsung BiologicsLtd (KRX:207940) Is Using Debt Reasonably Well

What Kind Of Shareholders Own Samsung Biologics Co.,Ltd. (KRX:207940)?

How Much Is Samsung Biologics Co.,Ltd. (KRX:207940) CEO Getting Paid?

New 90-day high: ₩825,000

Samsung Biologics Announces Strategic Manufacturing Partnership with Lilly to Accelerate Delivery of COVID-19 Antibody Treatments

Did You Miss Samsung BiologicsLtd's (KRX:207940) Impressive 112% Share Price Gain?

FibroGen, Inc. Enters into a Master Services Agreement with Samsung Biologics Co., Ltd

Samsung Biologics and Checkpoint Therapeutics Expand Manufacturing Partnership for Cosibelimab

Samsung Biologics Establishes Partnership with GeneQuantum Healthcare to Collaborate on ADC Development

New 90-day low: ₩658,000

Samsung Biologics Co.,Ltd. to Report Nine Months, 2020 Results on Oct 21, 2020

Samsung Biologics Signs Strategic Partnership with Kanaph Therapeutics to Develop Treatment for Retinal Diseases

New 90-day low: ₩705,000

Samsung Biologics and Astrazeneca Forge Strategic Manufacturing Partnership for Global Supply

Samsung Biologics Signs Development Agreement with Panolos for Solid Tumor Treatment

Price target raised to ₩843,438

New 90-day high - ₩843,000

Earnings released

Samsung Biologics Co.,Ltd. to Report First Half, 2020 Results on Jul 21, 2020

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies